Ind-Swift Labs gets USFDA EIR for Derabassi API facility
Advertisement
Mumbai: Ind-Swift Laboratories Limited has received the Establishment Inspection Report (EIR) from the USFDA, for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab.
"The USFDA inspection was conducted from 09th March 2020 to 13th March 2020. The EIR has been issued without any FORM 483 observations", Company added
This is the Sixth Successful USFDA inspection completed by the Company. IndSwift Supplies 15 APIs to its customers based in the U.S.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.